Indications

Huntington Disease with Chorea (see Huntington Disease)

General Comments

• xxxx

Clinical Efficacy

• xxxx

Restless Legs Syndrome (RLS) (see Restless Legs Syndrome)

General Comments

• xxxx

Clinical Efficacy

• xxxx

Tardive Dyskinesia (TD) (see Tardive Dyskinesia)

General Comments

• Off-Label Use

Clinical Efficacy

• xxx

Tourette Syndrome (see Tourette Syndrome)

General Comments

• Canadian Labeling

Clinical Efficacy

• xxx

---

Contraindications

• Levodopa-Induced Dyskinesia (see xxxx)

---

Pharmacology

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (see Vesicular Monoamine Transporter 2 Inhibitors)

• Central Monoamine-Depleting Agent
  • Depletes Presynaptic Dopamine Stores

Metabolism

• xxxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

Use in Pregnancy (see Pregnancy)

• xxx

Use in Lactation

• xxxx

---

Adverse Effects

General Comments

• Adverse Effects Listed Here Have Been Reported in Adults Treated with Tetrabenazine for Chorea Due to Huntington Disease
• Many Adverse Effects Listed Here are Dose-Related (and May Decrease at Lower Doses)

Cardiovascular Adverse Effects

• Orthostatic Hypotension (see xxxx)
• QT Prolongation (see Torsade)
  • Pharmacology: minimal prolongation of Q-T interval when used alone (although may be additive when used with other agents with Q-T prolonging effects)

Endocrinologic Adverse Effects

• Hyperprolactinemia (see Hyperprolactinemia)

Gastrointestinal Adverse Effects

• Anorexia (see Anorexia): occurs in 4% of cases
• Diarrhea (see xxxx): occurs in 2% of cases
• Dysphagia/Esophageal Dysmotility (see Dysphagia): occurs in 4-10% of cases
  • May Increase the Risk of Aspiration
• Nausea/Vomiting (see Nausea and Vomiting): nausea occurs in 13% of cases, vomiting occurs in 6% of cases

Neurologic Adverse Effects

• Akathisia (see xxxx): occurs in 19-20% of cases
• Anxiety (see xxxx): occurs in 15% of cases
• Central Nervous System Depression
  • Drowsiness: occurs in 17-57% of cases
• Depression/Suicidal Ideation (see Depression): occurs in 19-35% of cases
  • FDA Black Box Warning
• Dizziness (see Dizziness): occurs on 4% of cases
• Dysarthria (see Dysarthria): occurs in 4% of cases
• Equilibrium Distrubance: occurs in 9% of cases
• Extrapyramidal Symptoms (see Extrapyramidal Symptoms): overall, occur in 15-33% of cases
  • Drug-Induced Parkinsonism (see Parkinsonism): overall, occurs in 3-10% of cases
    • Bradykinesia (see Bradykinesia): occurs in 9% of cases
  • Tardive Dyskinesia (TD) (see Tardive Dyskinesia, [[Tardive Dyskinesia]]): may occur in some cases
• Falls: occurs in 15% of cases
• Fatigue (see Fatigue): occurs in 22% of cases
• Gait Disturbance: occurs in 4% of cases
• Headache (see Headache): occurs in 4% of cases
• Insomnia (see Insomnia): occurs on 22% of cases
• Irritability: occurs in 9% of cases
• Obsessive Rumination: occurs in 4% of cases

Ophthalmologic Adverse Effects

• Ophthalmic Effects: binds to melanin-containing tissues in animal studies

Renal Adverse Effects

• Dysuria (see xxxx): occurs in 4% of cases

Respiratory Adverse Effects

• Bronchitis (see xxxx): occurs in 4% of cases
• Dyspnea (see xxxx): occurs in 4% of cases
• Upper Respiratory Tract Infection (URI): occurs in 11% of cases

Other

• Neuroleptic Malignant Syndrome (NMS) (see Neuroleptic Malignant Syndrome)

---

References

• xxxx